Task order title: evaluation of real-time metabolic imaging biomarkers for detection of pancreatic premalignant lesions
Ended Awarded Last action
- Contract number
- 75N91021F00003
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,162,922
Award facts
- Contract value 100% obligated
- $1,162,921.53 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$3,352 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,166,274 |
About this award
This is a $1,162,921.53 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas M.D. Anderson Cancer Center (MD Anderson) for the "Evaluation of Real-Time Metabolic Imaging Biomarkers for Detection of Pancreatic Premalignant Lesions".
The contract is part of the larger "PREVENT Preclinical Drug Development Program: Preclinical Efficacy & Intermediate Biomarkers" indefinite delivery, indefinite quantity (IDIQ) contract, which has a ceiling value of $149,995,000. Under this IDIQ, MD Anderson conducts comprehensive preclinical research supporting drug and vaccine development from discovery through clinical stages. This specific delivery order is focused on evaluating real-time metabolic imaging biomarkers for detecting pancreatic premalignant lesions as part of the PREVENT program's preclinical efficacy and biomarker work. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N91021F00003?
75N91021F00003 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 16, 2021.
How much is contract 75N91021F00003 worth?
The government has obligated $1,162,922 on 75N91021F00003.
Is contract 75N91021F00003 an order under another contract?
Yes. 75N91021F00003 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91021F00003 competed?
The extent of competition for 75N91021F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award